Allspring Global Investments Holdings LLC Makes New Investment in Immunocore Holdings plc (NASDAQ:IMCR)

Allspring Global Investments Holdings LLC bought a new stake in shares of Immunocore Holdings plc (NASDAQ:IMCRGet Rating) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 95,660 shares of the company’s stock, valued at approximately $4,490,000. Allspring Global Investments Holdings LLC owned approximately 0.22% of Immunocore at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in shares of Immunocore by 27.3% during the 2nd quarter. Principal Financial Group Inc. now owns 299,950 shares of the company’s stock valued at $11,191,000 after purchasing an additional 64,405 shares in the last quarter. Rhenman & Partners Asset Management AB increased its holdings in shares of Immunocore by 89.4% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 170,472 shares of the company’s stock valued at $5,097,000 after purchasing an additional 80,472 shares in the last quarter. CWM LLC purchased a new position in shares of Immunocore during the 2nd quarter valued at approximately $2,725,000. Renaissance Technologies LLC increased its holdings in shares of Immunocore by 597.3% during the 2nd quarter. Renaissance Technologies LLC now owns 50,900 shares of the company’s stock valued at $1,899,000 after purchasing an additional 43,600 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Immunocore by 6,006.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 42,009 shares of the company’s stock valued at $1,567,000 after purchasing an additional 41,321 shares in the last quarter. 65.11% of the stock is owned by hedge funds and other institutional investors.

Immunocore Trading Up 4.5 %

Shares of IMCR opened at $63.54 on Tuesday. Immunocore Holdings plc has a 52-week low of $18.43 and a 52-week high of $69.06. The company has a quick ratio of 5.21, a current ratio of 5.23 and a debt-to-equity ratio of 0.25. The firm’s fifty day moving average is $59.21 and its two-hundred day moving average is $52.34. The stock has a market cap of $2.79 billion, a PE ratio of -36.94 and a beta of 0.55.

Immunocore (NASDAQ:IMCRGet Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.40. Immunocore had a negative net margin of 59.17% and a negative return on equity of 29.53%. The company had revenue of $48.52 million for the quarter, compared to analysts’ expectations of $37.73 million. Research analysts forecast that Immunocore Holdings plc will post -0.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IMCR has been the topic of a number of research analyst reports. HC Wainwright lifted their price target on shares of Immunocore from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, November 21st. Morgan Stanley lifted their price target on shares of Immunocore from $72.00 to $79.00 and gave the company an “overweight” rating in a research note on Thursday, November 10th. Barclays initiated coverage on shares of Immunocore in a research note on Wednesday, November 30th. They issued an “overweight” rating and a $80.00 price target on the stock. Finally, The Goldman Sachs Group raised shares of Immunocore from a “neutral” rating to a “buy” rating and lifted their price target for the company from $33.00 to $80.00 in a research note on Friday, December 16th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunocore has an average rating of “Buy” and a consensus price target of $79.13.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Further Reading

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCRGet Rating).

Institutional Ownership by Quarter for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.